249 related articles for article (PubMed ID: 37796436)
1. Outer Membrane Vesicle Vaccine Platforms.
Micoli F; Adamo R; Nakakana U
BioDrugs; 2024 Jan; 38(1):47-59. PubMed ID: 37796436
[TBL] [Abstract][Full Text] [Related]
2. Outer membrane vesicles as platform vaccine technology.
van der Pol L; Stork M; van der Ley P
Biotechnol J; 2015 Sep; 10(11):1689-706. PubMed ID: 26912077
[TBL] [Abstract][Full Text] [Related]
3. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification.
Gerritzen MJH; Salverda MLM; Martens DE; Wijffels RH; Stork M
Vaccine; 2019 Nov; 37(47):6978-6986. PubMed ID: 31383485
[TBL] [Abstract][Full Text] [Related]
4. High dissolved oxygen tension triggers outer membrane vesicle formation by Neisseria meningitidis.
Gerritzen MJH; Maas RHW; van den Ijssel J; van Keulen L; Martens DE; Wijffels RH; Stork M
Microb Cell Fact; 2018 Oct; 17(1):157. PubMed ID: 30285743
[TBL] [Abstract][Full Text] [Related]
5. A basis for vaccine development: Comparative characterization of Haemophilus influenzae outer membrane vesicles.
Roier S; Blume T; Klug L; Wagner GE; Elhenawy W; Zangger K; Prassl R; Reidl J; Daum G; Feldman MF; Schild S
Int J Med Microbiol; 2015 May; 305(3):298-309. PubMed ID: 25592265
[TBL] [Abstract][Full Text] [Related]
6. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in various bio-applications of bacteria-derived outer membrane vesicles.
Sadeghi L; Mohit E; Moallemi S; Ahmadi FM; Bolhassani A
Microb Pathog; 2023 Dec; 185():106440. PubMed ID: 37931826
[TBL] [Abstract][Full Text] [Related]
8. Engineered Bacterial Outer Membrane Vesicles with Lipidated Heterologous Antigen as an Adjuvant-Free Vaccine Platform for Streptococcus suis.
Li Q; Zhou G; Fei X; Tian Y; Wang S; Shi H
Appl Environ Microbiol; 2023 Mar; 89(3):e0204722. PubMed ID: 36809058
[TBL] [Abstract][Full Text] [Related]
9. Glycoengineered Outer Membrane Vesicles as a Platform for Vaccine Development.
Valguarnera E; Feldman MF
Methods Enzymol; 2017; 597():285-310. PubMed ID: 28935107
[TBL] [Abstract][Full Text] [Related]
10. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial.
Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ
mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Nontypeable Haemophilus influenzae Outer Membrane Vesicles and Protective Ability in the Chinchilla Model of Otitis Media.
Winter LE; Barenkamp SJ
Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28768669
[TBL] [Abstract][Full Text] [Related]
12. Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles.
Salverda ML; Meinderts SM; Hamstra HJ; Wagemakers A; Hovius JW; van der Ark A; Stork M; van der Ley P
Vaccine; 2016 Feb; 34(8):1025-33. PubMed ID: 26801064
[TBL] [Abstract][Full Text] [Related]
13. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
[TBL] [Abstract][Full Text] [Related]
14. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
15. Outer membrane vesicles as a platform for the discovery of antibodies to bacterial pathogens.
Lei EK; Azmat A; Henry KA; Hussack G
Appl Microbiol Biotechnol; 2024 Feb; 108(1):232. PubMed ID: 38396192
[TBL] [Abstract][Full Text] [Related]
16. Sulfate depletion triggers overproduction of phospholipids and the release of outer membrane vesicles by Neisseria meningitidis.
Gerritzen MJH; Martens DE; Uittenbogaard JP; Wijffels RH; Stork M
Sci Rep; 2019 Mar; 9(1):4716. PubMed ID: 30886228
[TBL] [Abstract][Full Text] [Related]
17. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.
Uli L; Castellanos-Serra L; Betancourt L; Domínguez F; Barberá R; Sotolongo F; Guillén G; Pajón Feyt R
Proteomics; 2006 Jun; 6(11):3389-99. PubMed ID: 16673438
[TBL] [Abstract][Full Text] [Related]
18. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
Holst J
Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
Sanders H; Feavers IM
Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
[TBL] [Abstract][Full Text] [Related]
20. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
